Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel for ADHD
ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) and Addrenex Pharmaceuticals today announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) showed statistically significant improvement over placebo.